Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2800-2810

  Pardi, Elena ^a   Marcocci, Claudio ^a   Borsari, Simona ^a   Saponaro, Federica ^a   Torregrossa, Liborio ^a   Tancredi, Mariella ^a   Raspini, Benedetta ^a   Basolo, Fulvio ^a   Cetani, Filomena ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; CHAPERONE; UNCLASSIFIED DRUG;

ADULT; AGED; AIP GENE; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; CHROMOSOME 11Q; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE DUPLICATION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEN1 GENE; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PARATHYROID ADENOMA; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SOMATIC MUTATION; SPORADIC PARATHYROID ADENOMA;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; FEMALE; GENE DELETION; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ITALY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 84879901175     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4029     Document Type: Article

References (38)

1. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389-2397.
2. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863-1875. (Pubitemid 32104134)
3. Cetani F, Pardi E, Borsari S, Marcocci C. Molecular pathogenesis of primary hyperparathyroidism. J Endocrinol Invest. 2011;34:35-39.
4. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N30-N36. (Pubitemid 35222310)
5. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA. 2006;103:15558-15563. (Pubitemid 44625631)
6. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011;96:E701-E706.
7. Cromer MK, Starker LF, Choi M, et al. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab. 2012;97:E1774-E1781.
8. Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012;97:E1995-E2005.
9. Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol. 2011;210:137-155.
10. Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16:1029-1043.
11. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93:2390-2401. (Pubitemid 351831563)
12. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228-1230. (Pubitemid 43801151)
13. Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21:419-427.
14. Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol. 2010;326:71-79.
15. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA. 2007;104:4101-4105. (Pubitemid 47181585)
16. Barlier A, Vanbellinghen JF, Daly AF, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92:1952-1955. (Pubitemid 46997216)
17. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf). 2007;66:499-502. (Pubitemid 46434927)
18. Raitila A, Georgitsi M, Karhu A, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer. 2007;14:901-906. (Pubitemid 350074077)
19. Vierimaa O, Villablanca A, Alimov A, et al. Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. J Endocrinol Invest. 2009;32:512-518.
20. Belar O, De la Hoz C, Perez-Nanclares G, Castano L, Gaztambide S. Novel mutations in men1, CDKN1b and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf). 2011;76:719-724.
21. Cetani F, Pinchera A, Pardi E, et al. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res. 1999;14:878-882. (Pubitemid 29262881)
22. Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89:5583-5591. (Pubitemid 39518444)
23. Cetani F, Pardi E, Giovannetti A, et al. Six novel MEN1 gene mutations in sporadic parathyroid tumors. Hum Mutat. 2000;16:445-448.
24. Occhi G, Trivellin G, Ceccato F, et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 2010;163:369-376.
25. Igreja S, Chahal HS, King P, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31:950-960.
26. Cazabat L, Libè R, Perlemoine K, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol. 2007;157:1-8. (Pubitemid 47162559)
27. Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165:509-515.
28. Ohanian M, Otway R, Fatkin D. Heuristic methods for finding pathogenic variants in gene coding sequences. J Am Heart Assoc. 2012;1:e002642.
29. Cuny T, Pertuit M, Sahnoun-Fathallah M, et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: Besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol. 2013;168:533-541.
30. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22-32.
31. Mallya SM, Gallagher JJ, Arnold A. Analysis of microsatellite instability in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2003;88:1248-1251. (Pubitemid 36337785)
32. Alvelos MI, Vinagre J, Fonseca E, et al. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. Eur J Endocrinol. 2013;168:119-128.
33. Vargiolu M, Fusco D, Kurelac I, et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J Clin Endocrinol Metab. 2009;94:2571-2578.
34. Morgan RM, Hernandez-Ramirez LC, Trivellin G, et al. Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition. PLoS One. 2012;7:e53339.
35. Cetani F, Pardi E, Ambrogini E, et al. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr Relat Cancer. 2007;14:493-499. (Pubitemid 47242647)
36. Wolpert HR, Vickery AL Jr, Wang CA. Functioning oxyphil cell adenomas of the parathyroid gland. A study of 15 cases. Am J Surg Pathol. 1989;13:500-504. (Pubitemid 19149612)
37. Fleischer J, Becker C, Hamele-Bena D, Breen TL, Silverberg SJ. Oxyphil parathyroid adenoma: a malignant presentation of a benign disease. J Clin Endocrinol Metab. 2004;89:5948-5951. (Pubitemid 39628398)
38. Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373-E383.